• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The analgesic effectiveness of an tramadol is significantly enhanced by administering tramadol prior to, with or following the administration of an analgesia enhancer which is a nontoxic NMDA receptor blocker and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.
    公开号:US20010008889A1
    申请号:US09/780,858
    申请日:2001-02-09
    公开日:2001-07-19
    发明作者:Frank Caruso；Fredrick Minn；John Lyle
    申请人:Caruso Frank S.；Minn Fredrick L.；Lyle John W.；
    IPC主号:A61K45-06
    专利说明:
    [0001] This invention relates to a composition and method for alleviating neuropathic pain. More particularly, this invention is directed to a composition and method for alleviating neuropathic pain in which a neuropathic pain-alleviating amount of an anticonvulsant is combined with an anticonvulsant-potentiating amount of a nontoxic antagonist, or blocker, for the N-methyl-D-aspartate (NMDA) receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation. [0001]
    [0002] Neuropathic pain is pain that is due to functional abnormalities of the nervous system. Fields, “Pain”, McGraw-Hill, Inc. (1987), pp. 133 et seq. There are a variety of possible mechanisms by which nerve dysfunction can cause neuropathic pain: hyperactivity in primary afferent or central nervous system (CNS) nociceptive neurons, loss of central inhibitory connections, and increased activity in sympathetic efferents. Neuropathic pain typically occurs following injury to elements of the nervous system involved in nociception, such as peripheral nerve injury, in which the lesions deafferent the nociceptive pathway, the resultant pain sometimes being referred to deafferentation pain. Neuropathic pain is much more likely to occur with peripheral than with central nervous system damage. Examples of causes of painful nerve injury are: accidental trauma, tumors, cerval or lumbar spine disease, and surgical procedures. These injuries usually involve one or two peripheral nerves or nerve roots, and the pain is felt in the body region normally innervated by the damaged nerves. Additionally, there are also toxic, metabolic, and hereditary causes of painful polyneuropathies, e.g., alcohol abuse, diabetes mellitus. These tend to be symmetrical and are most severe on the distal limbs. [0002] SUMMARY OF THE INVENTION
    [0003] In accordance with the present invention, a drug composition is provided which comprises a neuropathic pain-alleviating amount of at least one anticonvulsant in combination with an anticonvulsant-potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation. [0003]
    [0004] Further in accordance with the present invention, a method of alleviating neuropathic pain is provided which comprises administering to a mammal exhibiting neuropathic pain (a) a neuropathic pain-alleviating amount of at least one anticonvulsant and (b) an anticonvulsant-potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation with (a) being administered prior to, with or following the administration of (b). [0004]
    [0005] The expression “N-methyl-D-aspartate receptor” shall be understood to include all of the binding site subcategories associated with the NMDA receptor, e.g., the glycine-binding site, the phenylcyclidine (PCP)-binding site, etc., as well as the NMDA channel. Thus, the invention herein contemplates the use of nontoxic substances that block an NMDA receptor binding site, e.g., dextrorphan, or the NMDA channel, e.g., a source of magnesium such as magnesium sulfate. [0005]
    [0006] The term “nontoxic” as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration (“FDA”) for administration to humans or, in keeping with established regulatory criteria and practice, is susceptible to approval by the FDA for administration to humans. The term “nontoxic” is also used herein to distinguish the NMDA receptor antagonists, or blockers, that are useful in the practice of the present invention from NMDA receptor antagonists such as MK 801 (the compound 5-methyl-10,11-dihydro-SH-dibenze[a,d] cyclohepten-5,10-imine), CPP (the compound 3-[2-carboxypiperazin-4-yl] propyl-1-phosphonic acid) and PCP (the compound 1-(1-phenylcyclohexyl)piperidine) whose toxicities effectively preclude their therapeutic use. [0006]
    [0007] The expression “neuropathic pain-alleviating” shall be understood herein to include the expressions “neuropathic pain-suppressing” and “neuropathic pain-inhibiting” as the invention is applicable to the alleviation of existing neuropathic pain as well as the suppression or inhibition of neuropathic pain which would otherwise ensue from an imminent neuropathic pain-causing event. [0007] DESCRIPTION OF THE PREFERRED EMBODIMENTS
    [0008] Any of the pain-alleviating anticonvulsants can be used herein. For extensive listings of anticonvulsants, see, e.g., Goodman and Gilman's “The Pharmaceutical Basis Of Therapeutics”, 8th ed., McGraw-Hill, Inc. (1990), pp. 436-462, and “Remington's Pharmaceutical Sciences”, 17th ed., Mack Publishing Company (1985), pp. 1075-1083. Specific neuropathic pain-alleviating anticonvulsants that can be used herein include lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan. [0008]
    [0009] Among the nontoxic substances that block the NMDA receptor and as such are useful for potentiating the neuropathic pain-alleviating activity of the anticonvulsant in accordance with this invention are dextromethorphan ((+)-3-hydroxy-N-methylmorphinan), its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), amantadine (1-amino adamantine), memantine (3,5 dimethylaminoadamantone), their mixtures and their pharmaceutically acceptable salts. Other useful nontoxic substances that block the NMDA receptor include pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid. [0009]
    [0010] In addition to, or in place of, a blocker for the NMDA receptor, at least one nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation can also be used. Activation of the NMDA receptor, a subtype of excitatory amino acid receptors, induces a number of changes in the functional activity of nerve cells and, in particular, their capacity for excitability or inhibition in the presence of an addictive substance via an increase in intracellular Ca++ concentration. The major consequences of NMDA receptor activation include the following sequences, or cascades, of events occurring within nerve cells: [0010]
    [0011] a) translocation and activation of protein kinases such as protein kinase C → phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc. → changes in functional activity; [0011]
    [0012] b) initiation of early gene (c-ƒos, c-jun, ziƒ-268, etc.) expression by either increased intracellular Ca++ or Ca++-activated protein kinases → expression of functional genes responsible for production of cellular enzymes (such as protein kinases), receptor proteins (such as the NMDA receptor), ion channel proteins (such as K+, Na+, Ca++ channels), neuropeptides (such as dynorphin), etc. → changes in functional activity; [0012]
    [0013] c) Ca++/calmodulin (or other Ca++ binding proteins) induced activation of enzymes and other cellular components → activation of Ca++/calmodulin-protein kinase systems such as Ca++/calmodulin kinase II → autophosphorylation of enzymes (e.g., Ca++/calmodulin kinase II) or other functional proteins → changes in functional activity; [0013]
    [0014] d) Ca++/calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase → production of nitric oxide → i) production of cyclic guanosine monophosphate via activation of guanosine cyclase resulting in activation of protein kinases and early gene expression; ii) direct protein modification such as enzymes, receptor and/or channel proteins; iii) lipid membrane modification and/or nucleic acid modification via scavenge of free radicals; iv) induction of neurotoxicity at higher nitric oxide levels; v) retrograde actions in adjacent neurons or glial cells such as facilitation of glutamate release/NMDA receptor activation and/or inhibition of post-synaptic NMDA receptors → changes in functional activity; [0014]
    [0015] e) interactions with the cyclic adenosine monophosphate/protein kinase A system, the phospholipase C-inositol triphosphate-Ca++/diacylglycerol-protein kinase system, the phospholipase A2-arachidonic acid/prostanoids/leukotrienes system → changes in functional activity induced by second messenger systems other than NMDA receptor/Ca[0015] ++/Ca++-calmodulin/protein kinase systems; and,
    [0016] f) interactions with other excitatory amino acid receptor subtypes including non-NMDA receptors and metabotropic receptors as well as intracellular events subsequent to the activation of these excitatory amino acid receptor subtypes → changes in functional activity induced by the non-NMDA and metabotropic receptor activation. [0016]
    [0017] A substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place. However, even with activation of the NMDA receptor, it is still possible to treat neuropathic pain in accordance with this invention by administering the anticonvulsant and a nontoxic substance that blocks at least one of the foregoing major intracellular sequences of events brought about by activation of the NMDA receptor. Thus, e.g., a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention. [0017]
    [0018] Nontoxic substances that block a major intracellular consequence of NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C, e.g., gangliosides such as ganglioside GM[0018] I (monosialoganglioside) and ganglioside GTIb (trisialoganglioside); amphipathic long chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2-ones such as 4-methyl-5-(3-quinolinyl)-2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1,4-bis-(aminohydroxyalkylamino)-anthraquinones such as 1,4-bis-(3-propylamino-2-hydroxypropylamino)-9,10 anthracenedione and 1,4-bis-(3-benzylamino-2-hydroxypropylamino)-9,10 anthracenedione; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.
    [0019] Additional nontoxic substances that block a major intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine, fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-naphthalenesulfonamide and N-(6-aminohexyl)-5-bromo-2-naphthalenesulfonamide; 4-substituted-4H,6H-pyrrolo[ 1,2-a][4,1] benzoxazepines such as 1,3-dihydro-1-{1-[ (4-methyl-4H,6H-pyrrolo[1,2-a][4,1] benzoxazepin-4-yl)methyl]-4-piperidinyl}-2H-benzimidazol-2-one; benzhydryls such as N-[2](diphenylmethylthioethyl]-2-(trifluoromethyl)benzeneethanamine, N-[2-(bis(4-fluorophenyl)methylthio)ethyl]-2-(trifluoromethyl)benzeneethanamine and N-[2-(bis(4-fluorophenyl)methylthio)ethyl] -3-(trifluoromethyl)benzeneethanamine; tricyclic antidepressant drugs such as imipramine, 2-chloroimipramine and amitriptyline; penfluridol; haloperidol; pimozide; clozapine; calmidazolin; and, mixtures and pharmaceutically acceptable salts of any of the foregoing. [0019]
    [0020] Of the two groups, the NMDA-receptor antagonists are preferred and of these, dextromethorphan is especially preferred due to its wide use in over-the-counter medications where it functions as a cough suppressant. [0020]
    [0021] With regard to dosage levels, the anticonvulsant must be present in a neuropathic pain-alleviating amount, e.g., at a level corresponding to the generally recommended adult human dosages for a particular anticonvulsant, and the NMDA receptor blocker or substance that blocks a major intracellular consequence of NMDA activation must be present at a level that potentiates the neuropathic pain-alleviating effectiveness of the anticonvulsant. Specific dosage levels for the anticonvulsants that can be used herein as given, inter alia, in the “Physicians' Desk Reference”, 1996 Edition (Medical Economics Data Production Company, Montvale, N.J.) as well as in other reference works including Goodman and Gilman's “The Pharmaceutical Basis of Therapeutics” and “Remington's Pharmaceutical Sciences” both of which as referred to above. Given the wide variation in dosage level of the anticonvulsant which depends to a large extent on the specific anticonvulsant being administered, there can similarly be a wide variation in the dosage level of the NMDA receptor blocker or substance that blocks a major intracellular consequence of NMDA receptor activation. These amounts can be determined for a particular drug combination in accordance with this invention employing routine experimental testing. In case of the anticonvulsant phenobarbital and the NMDA receptor blocker dextromethorphan, dosages of from 50 to 300 mg/day of the former coadministered with from 30 to 120 mg/day of the latter will usually provide acceptable results. [0021]
    [0022] While the neuropathic pain-alleviating anticonvulsant and anticonvulsant-potentiating nontoxic NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation need not be administered together, they must both be present in the patient at effective levels at the same time. While it is within the scope of the invention to separately administer the anticonvulsant and the NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation, as a matter of convenience, it is preferred that these drugs be coadministered in a single dosage form. All modes of administrations are contemplated, e.g., orally, rectally, parenterally, intranasally and topically. [0022]
    [0023] A therapeutic composition containing the anticonvulsant and nontoxic NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation will ordinarily be formulated with one or more pharmaceutically acceptable ingredients in accordance with known and established practice. Thus, the composition can be formulated as a liquid, powder, elixir, injectable solution, etc. Formulations for oral use can be provided as tablets or hard capsules wherein the pharmacologically active ingredients are mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients are mixed with an oleaginous medium, e.g., liquid paraffin or olive oil. [0023]
    [0024] Aqueous suspensions can include pharmaceutically acceptable excipients such as suspending agents, e.g., sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., polyoxyethylene sorbitan monoleate. The aqueous suspensions can also contain one or more preservatives, e.g., ethyl-or-n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate. [0024]
    [0025] In addition to anticonvulsant and nontoxic NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation, the therapeutic composition herein can optionally contain at least one other pharmacologically active substance e.g., a non-narcotic analgesic such as acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, zomepirac, and the like. [0025]
    权利要求:
    Claims (19)
    [1" id="US-20010008889-A1-CLM-00001] 1. A therapeutic composition comprising (a) a neuropathic pain-alleviating amount of at least one anticonvulsant and (b) an anticonvulsant-potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.
    [2" id="US-20010008889-A1-CLM-00002] 2. The therapeutic composition of
    claim 1 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan.
    [3" id="US-20010008889-A1-CLM-00003] 3. The therapeutic composition of
    claim 1 wherein nontoxic NMDA receptor blocker (b) is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof.
    [4" id="US-20010008889-A1-CLM-00004] 4. The therapeutic composition of
    claim 1 wherein (a) and (b) each is present in the same or different sustained release carrier.
    [5" id="US-20010008889-A1-CLM-00005] 5. The therapeutic composition of
    claim 1 containing a therapeutically effective amount of at least one other pharmacologically active substance (c).
    [6" id="US-20010008889-A1-CLM-00006] 6. The therapeutic composition of
    claim 1 containing a therapeutically effective amount of at least one other pharmacologically effective substance (c) selected from the group consisting of acetaminophen and nonsteroidal anti-inflammatory drug.
    [7" id="US-20010008889-A1-CLM-00007] 7. The therapeutic composition of
    claim 1 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is dextromethorphan, or pharmaceutically acceptable salt thereof.
    [8" id="US-20010008889-A1-CLM-00008] 8. A method of alleviating neuropathic pain which comprises administering to a mammal exhibiting neuropathic pain (a) a neuropathic pain-alleviating amount of at least one anticonvulsant and (b) an anticonvulsant-potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation with (a) being administered prior to, with or following the administration of (b).
    [9" id="US-20010008889-A1-CLM-00009] 9. The method of
    claim 8 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan.
    [10" id="US-20010008889-A1-CLM-00010] 10. The method of
    claim 8 wherein nontoxic NMDA receptor blocker (b) is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof.
    [11" id="US-20010008889-A1-CLM-00011] 11. The method of
    claim 8 wherein (a) and (b) are coadministered as a sustained release dosage form.
    [12" id="US-20010008889-A1-CLM-00012] 12. The method of
    claim 8 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof and (a) and (b) are coadministered as a single dosage unit.
    [13" id="US-20010008889-A1-CLM-00013] 13. The method of
    claim 8 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is dextromethorphan, or pharmaceutically acceptable salt thereof.
    [14" id="US-20010008889-A1-CLM-00014] 14. The therapeutic composition of
    claim 1 further comprising (c) an analgesic.
    [15" id="US-20010008889-A1-CLM-00015] 15. The therapeutic composition of
    claim 14 wherein the analgesic is a non-narcotic analgesic.
    [16" id="US-20010008889-A1-CLM-00016] 16. The therapeutic composition of
    claim 15 wherein the non-narcotic analgesic is at least one member selected from the group consisting of acetaminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.
    [17" id="US-20010008889-A1-CLM-00017] 17. The method of
    claim 8 further comprising (c) an analgesic.
    [18" id="US-20010008889-A1-CLM-00018] 18. The method of
    claim 17 wherein the analgesic is a non-narcotic analgesic.
    [19" id="US-20010008889-A1-CLM-00019] 19. The method of
    claim 18 wherein the non-narcotic analgesic is at least one member selected from the group consisting of ace taminophen, aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6187338B1|2001-02-13|Anticonvulsant containing composition for treating neuropathic pain
    US5502058A|1996-03-26|Method for the treatment of pain
    US6054451A|2000-04-25|Analgesic composition and method for alleviating pain
    EP0938305B1|2005-08-17|Method of alleviating pain by means of combining tramadol with an nmda antagonist
    US20020035105A1|2002-03-21|Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain
    JP3924321B2|2007-06-06|Pain reducing pharmaceutical composition and pain reducing method
    US6043244A|2000-03-28|Method and composition for treating migraine
    KR100537707B1|2005-12-20|Analgesic Compositions Comprising Anti-epileptic Compounds and Methods of Using Same
    EP0229022A2|1987-07-15|Novel pharmaceutical compositions comprising analgesic agents or caffeine
    WO1999007413A1|1999-02-18|Substance p inhibitors in combination with nmda-blockers for treating pain
    EP0311677A1|1989-04-19|Cough/cold mixtures comprising non-sedating antihistamine drugs.
    RU2469717C2|2012-12-20|Combination of hda inhibitor and antimetabolite
    US5834479A|1998-11-10|Method and composition for alleviating pain
    SE466889B|1992-04-27|Analgesic and anti-inflammatory compositions consisting of ibuprofen and caffeine
    AU714653B2|2000-01-06|Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
    SE466481B|1992-02-24|ANALGETIC AND ANTI-INFLAMMATORY COMPOSITIONS INCLUDING COFFEE
    RU2213561C2|2003-10-10|Analgetic compositions containing non-narcotic analgetic and enhancer of analgesia
    EP0013110A1|1980-07-09|Analgesic composition
    EP0966286B1|2003-07-30|Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain
    MXPA01007012A|2002-03-05|Analgesic compositions comprising anti-epileptic compounds and methods of using same
    同族专利:
    公开号 | 公开日
    US6187338B1|2001-02-13|
    AU4078897A|1998-03-06|
    WO1998007447A1|1998-02-26|
    US6406716B2|2002-06-18|
    DE69733081T2|2006-05-11|
    EP0942752A1|1999-09-22|
    DE69733081D1|2005-05-25|
    CA2264182A1|1998-02-26|
    ES2241055T3|2005-10-16|
    EP0942752B1|2005-04-20|
    JP2001500121A|2001-01-09|
    AT293458T|2005-05-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20030225002A1|2002-02-26|2003-12-04|Livingstone Ian R.|Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents|
    US20050282887A1|2004-06-16|2005-12-22|Mccomsey David F|Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders|
    US20060041008A1|2004-06-16|2006-02-23|Mccomsey David F|Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders|
    US20060047001A1|2004-08-24|2006-03-02|Parker Michael H|Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents|
    US20060270856A1|2005-05-20|2006-11-30|Abdel-Magid Ahmed F|Process for preparation of sulfamide derivatives|
    US20070155826A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder|
    US20070155821A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels|
    US20070155822A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain|
    US20070155823A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents|
    US20070155827A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression|
    US20070155825A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction|
    US20070191461A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine|
    US20070191474A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine|
    US20070191449A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression|
    US20070293440A1|2006-05-19|2007-12-20|Smith-Swintosky Virginia L|Co-therapy for the treatment of epilepsy and related disorders|
    US20080027131A1|2005-12-19|2008-01-31|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity|
    US20090030078A1|2005-06-27|2009-01-29|Ono Pharmaceutical Co., Ltd.|Therapeutic agent for pain|
    US20090247617A1|2008-03-26|2009-10-01|Abdel-Magid Ahmed F|Process for the preparation of benzo-fused heteroaryl sulfamates|
    US20090247616A1|2008-03-26|2009-10-01|Smith-Swintosky Virginia L|Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety|
    US20100063138A1|2008-07-22|2010-03-11|Mccomsey David F|Novel substituted sulfamide derivatives|
    US20100247610A1|2001-10-25|2010-09-30|Bret Berner|Gastric retained gabapentin dosage form|
    US20110218246A1|2005-12-29|2011-09-08|Depomed, Inc|Methods of treating non-nociceptive pain states with gastric retentive gabapentin|
    US8440232B2|2001-10-25|2013-05-14|Depomed, Inc.|Methods of treatment using a gastric retained gabapentin dosage|
    US8592481B2|2005-12-29|2013-11-26|Depomed, Inc.|Gastric retentive gabapentin dosage forms and methods for using same|
    US8809385B2|2008-06-23|2014-08-19|Janssen Pharmaceutica Nv|Crystalline form of --N--sulfamide|US4694010A|1985-08-16|1987-09-15|New York University|Anticonvulsant compositions and method|
    WO1989005642A1|1987-12-22|1989-06-29|Ferkany John W|Dextrorphan potentiator for anticonvulsant composition and method|
    US4906638A|1987-12-22|1990-03-06|Nova Pharmaceutical Corporation|Dextromethorphan potentiator for anticonvulsant composition and method|
    US5075114A|1990-05-23|1991-12-24|Mcneil-Ppc, Inc.|Taste masking and sustained release coatings for pharmaceuticals|
    US5234929A|1992-07-20|1993-08-10|William Chelen|Method of treating motion sickness with anticonvulsants and antitussive agents|
    CA2115792C|1993-03-05|2005-11-01|David J. Mayer|Method for the treatment of pain|
    DE69733081T2|1996-08-23|2006-05-11|Endo Pharmaceuticals Inc. |ANTICONVULSIVE PREPARATION FOR THE TREATMENT OF NEUROPATHIC PAIN|
    US6057373A|1997-05-22|2000-05-02|Synchroneuron, Llc|Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists|DE69733081T2|1996-08-23|2006-05-11|Endo Pharmaceuticals Inc. |ANTICONVULSIVE PREPARATION FOR THE TREATMENT OF NEUROPATHIC PAIN|
    WO1999008670A1|1997-08-20|1999-02-25|Guglietta, Antonio|Gaba analogs to prevent and treat gastrointestinal damage|
    AU784225B2|1997-09-08|2006-02-23|Warner-Lambert Company|Analgesic compositions comprising anti-epileptic compounds and methods of using same|
    AU2002301362B8|1997-09-08|2006-05-04|Warner-Lambert Company|Analgesic compositions comprising anti-epileptic compounds and methods of using same|
    IL134165D0|1997-09-08|2001-04-30|Warner Lambert Co|Analgesic compositions comprising anti-epileptic compounds and methods of using same|
    AU772156B2|1998-07-09|2004-04-08|Warner-Lambert Company|Compositions comprising GABA analogs and caffeine|
    US6309858B1|1998-09-29|2001-10-30|SyntexLlc|T-type calcium channel variants; compositions thereof; and uses|
    DK1154996T3|1999-02-18|2004-02-16|Ortho Mcneil Pharm Inc|Aminoacylaroyl pyrrols for the treatment of neuropathic pain|
    US6451857B1|1999-03-10|2002-09-17|Warner-Lambert Company|Analgesic compositions comprising anti-epileptic compounds and methods of using same|
    JP2002541215A|1999-04-09|2002-12-03|ユーロ−セルティックエス．ア．|Sodium channel blocker compositions and uses thereof|
    AU5824800A|1999-06-23|2001-01-31|Warner-Lambert Company|Use of fosphenytoin for the treatment of acute neuropathic pain|
    PT1210118E|1999-08-20|2005-02-28|Ortho Mcneil Pharm Inc|COMPOSITION COMPOSING A TRAMADOL MATERIAL AND ANTICONVULSIVE PHARMACO|
    AU7163101A|2000-06-30|2002-01-14|Ortho Mcneil Pharm Inc|Useful aroyl aminoacyl pyrrole compounds|
    US20040122090A1|2001-12-07|2004-06-24|Lipton Stuart A.|Methods for treating neuropsychiatric disorders with nmda receptor antagonists|
    JP2005506292A|2001-03-08|2005-03-03|エモリー　ユニバーシティ|pH-dependent NMDA receptor antagonist|
    ES2632544T3|2001-06-07|2017-09-14|Analgesic Neuropharmaceuticals, Llc|Treatment of neuropathic pain with the N-methyl-D-aspartatedextromethorphan receptor antagonist|
    ITMI20011308A1|2001-06-21|2002-12-23|Nicox Sa|DRUGS FOR CHRONIC PAIN|
    ES2253579T3|2001-09-03|2006-06-01|Newron Pharmaceuticals S.P.A.|PHARMACEUTICAL COMPOSITION INCLUDING GABAPENTINA OR AN ANALOG OF HER AND AN ALPHA-AMINOAMIDE AND ITS ANALGESIC USE.|
    CA2473536A1|2002-01-16|2003-07-31|Endo Pharmaceuticals, Inc.|Pharmaceutical composition and method for treating disorders of the central nervous system|
    SG148850A1|2002-02-13|2009-01-29|Beth Israel Hospital|Methods of treating vascular disease|
    US8097585B2|2002-04-15|2012-01-17|Beth Israel Deaconess Medical Center, Inc.|Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation|
    CN1674942A|2002-06-21|2005-09-28|联邦高等教育系统匹兹堡大学|Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation|
    EP1524981B1|2002-07-29|2009-03-11|Glaxo Group Limited|Sustained release formulations comprising lamotrigine|
    US8637512B2|2002-07-29|2014-01-28|Glaxo Group Limited|Formulations and method of treatment|
    AU2003297639A1|2002-12-02|2004-06-23|University Of Florida|Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases|
    HU0300929A3|2003-04-09|2005-06-28|Richter Gedeon Vegyeszet|Analgetic and/or muscle relaxant pharmaceutical composition|
    EP1638931A4|2003-06-11|2007-11-07|Neuromolecular Inc|Method of targeting a therapeutic agent|
    US20040265364A1|2003-06-25|2004-12-30|Binnur Ozturk|Neuropathy cream|
    US20050169994A1|2003-11-25|2005-08-04|Burke Matthew D.|Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods|
    EP1715843A1|2004-01-29|2006-11-02|Neuromolecular Inc.|Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions|
    DE05852057T1|2004-11-23|2007-11-29|Neuromolecular Pharmaceuticals Inc., Emeryville|COMPOSITION OF A COATING OR MATRIX WITH DELAYED RELEASE AND A NMDA RECEPTOR ANTAGONIST AND METHOD FOR THE ADMINISTRATION OF SUCH A NMDA RECEPTOR ANTAGONIST TO A SUBJECT|
    WO2005079773A2|2004-02-13|2005-09-01|Neuromolecular, Inc.|Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders|
    US20060002999A1|2004-06-17|2006-01-05|Forest Laboratories, Inc.|Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane|
    US20060034910A1|2004-08-09|2006-02-16|Sanjay Patel|Pharmaceutical composition for extended release of phenytoin sodium|
    SI1809271T1|2004-09-10|2010-10-29|Newron Pharm Spa|Use of - benzylamino-propanamides as sodium and/or calcium channel selective modulators|
    AT481096T|2005-04-06|2010-10-15|Adamas Pharmaceuticals Inc|METHOD AND COMPOSITIONS FOR TREATING CNS DISEASES|
    US7619007B2|2004-11-23|2009-11-17|Adamas Pharmaceuticals, Inc.|Method and composition for administering an NMDA receptor antagonist to a subject|
    WO2006058236A2|2004-11-24|2006-06-01|Neuromolecular Pharmaceuticals, Inc.|Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease|
    US20060270742A1|2005-05-02|2006-11-30|Jane Staunton|Compositions and methods for the treatment of neurodegenerative diseases|
    WO2006122035A2|2005-05-06|2006-11-16|University Of Maryland, Baltimore|Method for treating central pain syndrome or for inducing centrally generated pain in an animal model|
    WO2007071311A1|2005-12-22|2007-06-28|Newron Pharmaceuticals S.P.A.|2 -phenylethylamino derivatives as calcium and/or sodium channel modulators|
    US20070191452A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain|
    WO2007120485A2|2006-03-30|2007-10-25|Cinergen, Llc|Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor|
    US20120083508A1|2006-12-22|2012-04-05|Allergan, Inc.|Alpha-2b receptor agonist and anticonvulsantcompositions for treating chronic pain|
    EP2124912B1|2006-12-22|2014-12-03|Allergan, Inc.|Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain|
    JP2010532382A|2007-06-29|2010-10-07|エモリー・ユニバーシテイ|NMDA receptor antagonist for neuroprotection|
    US20100279984A1|2007-10-09|2010-11-04|Merck Patent Gmbh|Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin|
    US20090247644A1|2008-03-28|2009-10-01|Forest Laboratories Holdings Limited|Memantine formulations|
    CA2738468A1|2008-09-27|2010-04-01|Taraxos Inc.|Topical formulations for treatment of neuropathy|
    CA2782556C|2009-12-02|2018-03-27|Adamas Pharmaceuticals, Inc.|Amantadine compositions and methods of use|
    US20110251239A1|2010-04-07|2011-10-13|Eisai Inc.|Combination therapy for the treatment of dementia|
    FR2998892B1|2012-12-04|2015-01-02|Pf Medicament|AMINOCYCLOBUTANE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS|
    WO2014204933A1|2013-06-17|2014-12-24|Adamas Pharmaceuticals, Inc.|Amantadine compositions and methods of use|
    EA032777B1|2013-12-24|2019-07-31|Вирджиния Коммонвелт Юниверсити|Method of preventing or treating kidney failure|
    US11147799B2|2016-12-06|2021-10-19|Jan Marius Keppel Hesselink|Topical pharmaceutical composition containing phenytoin and aanalgesic for the treatment of chronic pain|
    WO2020054872A1|2018-09-14|2020-03-19|国立大学法人富山大学|Therapeutic agent for acute herpes zoster pain|
    WO2021220284A1|2020-05-01|2021-11-04|Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.|E protein channel blockers and orf3 inhibitors as anti-covid-19 agents|
    法律状态:
    2002-02-12| AS| Assignment|Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: MERGER;ASSIGNOR:ENDO INC.;REEL/FRAME:012607/0400 Effective date: 20011231 |
    2003-01-28| CC| Certificate of correction|
    2005-11-16| FPAY| Fee payment|Year of fee payment: 4 |
    2009-10-19| AS| Assignment|Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT Free format text: SECURITY AGREEMENT;ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:023390/0120 Effective date: 20091016 |
    2009-11-20| FPAY| Fee payment|Year of fee payment: 8 |
    2010-12-01| AS| Assignment|Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT Free format text: SECURITY AGREEMENT;ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:025416/0381 Effective date: 20101130 |
    2010-12-03| AS| Assignment|Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: RELEASE OF PATENT SECURITY INTEREST RECORDED AT REEL/FRAME 23390/120;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:025441/0305 Effective date: 20101130 |
    2011-07-07| AS| Assignment|Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRA Free format text: SECURITY AGREEMENT;ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:026557/0350 Effective date: 20110617 |
    2011-07-11| AS| Assignment|Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 25416/381;ASSIGNOR:JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:026572/0148 Effective date: 20110617 |
    2014-01-24| REMI| Maintenance fee reminder mailed|
    2014-03-03| AS| Assignment|Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: RELEASE OF PATENT SECURITY INTEREST;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT;REEL/FRAME:032380/0198 Effective date: 20140228 |
    2014-06-18| LAPS| Lapse for failure to pay maintenance fees|
    2014-07-14| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2014-08-05| FP| Lapsed due to failure to pay maintenance fee|Effective date: 20140618 |
    优先权:
    申请号 | 申请日 | 专利标题
    US2450896P| true| 1996-08-23|1996-08-23||
    PCT/US1997/014680|WO1998007447A1|1996-08-23|1997-08-21|Anticonvulsant containing composition for treating neuropathic pain|
    US09/253,598|US6187338B1|1996-08-23|1999-02-22|Anticonvulsant containing composition for treating neuropathic pain|
    US09/780,858|US6406716B2|1996-08-23|2001-02-09|Anticonvulsant containing composition for treating neuropathic pain|US09/780,858| US6406716B2|1996-08-23|2001-02-09|Anticonvulsant containing composition for treating neuropathic pain|
    [返回顶部]